Global Cognitive Decline Treatment Market Strategic Research Report

Scope of the Report

The global Cognitive Decline Treatment market size is predicted to grow from US$ 103,235 million in 2025 to US$ 241,943 million in 2032; it is expected to grow at a CAGR of 7.5% from 2026 to 2032.

Cognitive decline treatment refers to a comprehensive medical intervention system that addresses the decline in memory, attention, executive function, and language abilities caused by aging, neurodegenerative diseases, brain injury, or metabolic diseases. It utilizes a combination of methods, including drug therapy, non-drug interventions, neuromodulation techniques, and digital therapies, to slow or improve the progression of cognitive decline. Its core objectives are to slow disease progression, improve patients' daily living abilities, and enhance their quality of life.

With the accelerating aging of the global population and the rapid increase in the number of people aged 65 and above, the incidence of cognitive decline-related diseases continues to rise, significantly expanding the demand for treatment and intervention. Simultaneously, in drug development, the entry of Aβ monoclonal antibodies into clinical application marks a breakthrough in disease-modifying therapy (DMT). Coupled with the development of digital therapies, AI-based early screening tools, brain-computer interfaces, and neuromodulation technologies, cognitive decline treatment is evolving from single-drug therapy to a comprehensive solution encompassing "drugs + devices + digital therapies + rehabilitation management." The market is expected to continue its rapid growth in the future, extending towards early screening, delaying onset, and long-term management.

This report presents a comprehensive overview of the global Cognitive Decline Treatment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Prescription Drugs
• Medical Devices
• Digital Therapy Software
• Rehabilitation Training Services
• Others

Segment by Intervention Stages

• Prevention Stage
• Early Intervention
• Intermediate Treatment
• Late-Stage Supportive Treatment

Segment by Technological Pathways

• Neurotransmitter Regulation Pathway
• Amyloid (Aβ) Clearance Pathway
• Tau Protein Targeting Pathway
• Neuroinflammatory Regulation Pathway
• Neuroplasticity Enhancement Pathway

Segment by Application

• Alzheimer's Disease (AD)
• Vascular Cognitive Impairment (VCI)
• Parkinson's-Related Cognitive Decline
• Post-Traumatic Brain Injury Cognitive Impairment
• Mild Cognitive Impairment (MCI)

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cognitive Decline Treatment market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Alzheimer's Disease (AD), Vascular Cognitive Impairment (VCI), Parkinson's-Related Cognitive Decline evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact